Rare Disease Report

RareDR.com

Rare Disease Report provides an independent voice to the rare disease community. Through our multi-channel distribution platform, we provide our audience of clinicians, advocates, patients, scientists, and pharma professionals, the up-to-date information relevant to the rare disease community.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

YELLOWDOG ACCELERATES DRUG DISCOVERY FROM ONE YEAR TO LESS THAN ONE DAY WITH A 162,120 CORE SUPERCOMPUTER, ON-DEMAND

Prnewswire | September 21, 2020

news image

In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by...

Read More

Pharmacy Market

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

news image

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

news image

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More

Pharmacy Market

TWELVE CONSULTING GROUP ANNOUNCES PARTNERSHIP WITH CELONIS TO HELP CUSTOMERS IDENTIFY AND ELIMINATE PROCESS INEFFICIENCIES

Twelve Consulting Group, | February 11, 2022

news image

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management. This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity. Read More

news image

YELLOWDOG ACCELERATES DRUG DISCOVERY FROM ONE YEAR TO LESS THAN ONE DAY WITH A 162,120 CORE SUPERCOMPUTER, ON-DEMAND

Prnewswire | September 21, 2020

In drug discovery, as with many of the life sciences, data is key. The size of a dataset and the quality of the analyses has a powerful influence on the success of a given drug development programme. There is great potential for the cloud to aid drug discovery, as it offers companies the ability to dynamically scale their research and analyse more data than they would with their on-premise infrastructure. OMass Therapeutics saw an opportunity to accelerate their virtual screening capabilities by...

Read More
news image

Pharmacy Market

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More
news image

Pharmacy Market

PAN-TB COLLABORATION ANNOUNCES THE START OF A PHASE 2 CLINICAL TRIAL TO EVALUATE TWO NOVEL TUBERCULOSIS TREATMENT REGIMENS

PRNewswire | August 10, 2023

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pu...

Read More
news image

Pharmacy Market

TWELVE CONSULTING GROUP ANNOUNCES PARTNERSHIP WITH CELONIS TO HELP CUSTOMERS IDENTIFY AND ELIMINATE PROCESS INEFFICIENCIES

Twelve Consulting Group, | February 11, 2022

Twelve Consulting Group, a consultancy firm specializingin designing and delivering cloud-based solutions, has formalized its partnership with Celonis, the global leader in execution management. This partnership combines Twelve CG’s technology consulting expertise with Celonis’ market leading process mining and execution management capabilities, enabling customers to optimize their business operations, identify inefficiencies and unlock their full execution capacity. Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us